Loading...
Loading...
TOVX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 131.0K |
| Gross Profit | -131.0K |
| Operating Expense | 5,820.0K |
| Operating I/L | -5,820.0K |
| Other Income/Expense | 377.0K |
| Interest Income | 381.0K |
| Pretax | -5,443.0K |
| Income Tax Expense | -359.0K |
| Net Income/Loss | -5,084.0K |
Theriva Biologics Inc. is a clinical-stage company focused on developing therapeutics to address high unmet medical needs. The company's lead product candidates include SYN-004, designed to prevent microbiome damage and infections caused by intravenous antibiotics, and SYN-020, an oral enzyme formulation for treating gastrointestinal and systemic diseases. Additionally, the company is developing VCN-01 for various cancer treatments and has collaborations with industry and academic partners. Theriva Biologics Inc. aims to generate revenue through the successful development and commercialization of its innovative therapeutic products targeting a range of diseases.
